Upgrade to SI Premium - Free Trial

Nuvectis Pharma (NVCT)

21.55 +0.96 (4.66%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 October 9, 2026 8:00 AM - StreetInsider Nuvectis drug NXP200 gets China breakthrough therapy status September 24, 2026 8:01 AM - StreetInsider Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma September 24, 2026 8:00 AM - Globe NewsWire Nuvectis Pharma To Participate in Upcoming Investor Conferences September 3, 2026 8:00 AM - StreetInsider Lucid Capital Markets Assumes Nuvectis Pharma (NVCT) at Buy September 1, 2026 6:12 AM - StreetInsider Cantor Fitzgerald Starts Nuvectis Pharma (NVCT) at Overweight August 24, 2026 6:19 AM - StreetInsider Nuvectis Pharma (NVCT) files $200M mixed shelf August 21, 2026 4:41 PM - StreetInsider Form S-3 Nuvectis Pharma, Inc. August 21, 2026 4:38 PM - SEC Filing Form 8-K Nuvectis Pharma, Inc. For: Jul 20 August 21, 2026 4:31 PM - SEC Filing Form SCHEDULE 13G Nuvectis Pharma, Inc. Filed by: Soleus Private Equity Fund III, L.P. August 6, 2026 11:29 AM - SEC Filing Form 4 Nuvectis Pharma, Inc. For: Aug 03 Filed by: Carson Michael J. August 5, 2026 5:26 PM - SEC Filing Form 10-Q Nuvectis Pharma, Inc. For: Jun 30 August 4, 2026 9:02 AM - SEC Filing Form 8-K Nuvectis Pharma, Inc. For: Aug 04 August 4, 2026 8:25 AM - SEC Filing Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights August 4, 2026 8:01 AM - Globe NewsWire Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors July 23, 2026 9:00 AM - StreetInsider China approves Nuvectis drug ciprocopan for PNH treatment July 23, 2026 7:30 AM - StreetInsider Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors July 23, 2026 7:30 AM - StreetInsider Full Article List